Last reviewed · How we verify

NCT03159663

Assessment of Quality of Life in Hemophiliac Patients

Status unknown Last updated 23 May 2017
What this trial tests

trial in Improvement of Quality of Life of Hemophiliac Patients in 100 participants. Status unknown.

Timeline
1 June 2017
Primary endpoint
1 June 2017
1 July 2018

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date1 June 2017
Primary completion1 June 2017
Estimated completion1 July 2018
Sites1 location across Egypt

Conditions studied

Sponsor

Assiut University

Who can join

Adults 10 to 70, male only, with Improvement of Quality of Life of Hemophiliac Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hemophilia is an X-linked congenital bleeding disorder caused by deficiency of coagulation factor VIII (in hemophilia A) or factor IX (in hemophilia B). The deficiency is the result of mutations of the respective clotting factor genes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03159663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing